339 related articles for article (PubMed ID: 3261631)
1. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
Yoshida S; Tanaka R; Takai N; Ono K
Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
[TBL] [Abstract][Full Text] [Related]
2. [Observations on the local administration of autologous lymphokine activated killer cells and recombinant interleukin-2 in patients with malignant gliomas].
Yoshida S; Takai N; Ono K; Saito T; Tanaka R
No To Shinkei; 1988 Feb; 40(2):119-25. PubMed ID: 3259433
[TBL] [Abstract][Full Text] [Related]
3. [Adoptive immunotherapy in patients with malignant glioma].
Yoshida S; Takai N; Saito T; Tanaka R
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1930-2. PubMed ID: 3496052
[TBL] [Abstract][Full Text] [Related]
4. Intratumoral LAK cell and interleukin-2 therapy of human gliomas.
Barba D; Saris SC; Holder C; Rosenberg SA; Oldfield EH
J Neurosurg; 1989 Feb; 70(2):175-82. PubMed ID: 2643685
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-2 or autologous lymphokine-activated killer cell treatment of malignant glioma: phase I trial.
Jacobs SK; Wilson DJ; Kornblith PL; Grimm EA
Cancer Res; 1986 Apr; 46(4 Pt 2):2101-4. PubMed ID: 3512079
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
[TBL] [Abstract][Full Text] [Related]
7. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans.
Boldt DH; Mills BJ; Gemlo BT; Holden H; Mier J; Paietta E; McMannis JD; Escobedo LV; Sniecinski I; Rayner AA
Cancer Res; 1988 Aug; 48(15):4409-16. PubMed ID: 3260537
[TBL] [Abstract][Full Text] [Related]
8. Scintigraphy with In-111 labeled lymphokine-activated killer cells of malignant brain tumor.
Itoh K; Sawamura Y; Hosokawa M; Kobayashi H
Radiat Med; 1988; 6(6):276-81. PubMed ID: 2854899
[TBL] [Abstract][Full Text] [Related]
9. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
10. [Clinical studies of adoptive immunotherapy of human disseminated brain tumors with LAK cells and recombinant interleukin-2].
Okamoto Y; Shimizu K; Miyao Y; Yamada M; Ushio Y; Matsui Y; Hayakawa T; Tago H; Ikeda H
No To Shinkei; 1986 Jun; 38(6):593-8. PubMed ID: 3488068
[TBL] [Abstract][Full Text] [Related]
11. [The anti-tumor efficacy of lymphokine-activated killer (LAK) cells induced in vitro from peripheral blood lymphocytes of patients with malignant glioma].
Shimizu K; Miyao Y; Okamoto Y; Matsui Y; Ushio Y; Tsuda N; Hayakawa T; Ishida N; Mogami H
No To Shinkei; 1986 Mar; 38(3):265-71. PubMed ID: 3085695
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy of malignant diseases with IL-2-activated lymphocytes.
Kimoto Y; Taguchi T
Biken J; 1987 Jun; 30(2):29-38. PubMed ID: 3501954
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells.
Holladay FP; Heitz T; Wood GW
J Neurosurg; 1992 Nov; 77(5):757-62. PubMed ID: 1403119
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
Takai N; Tanaka R; Yoshida S; Hara N; Saito T
Cancer Res; 1988 Apr; 48(8):2047-52. PubMed ID: 3258182
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-2 and lymphokine activated killer (LAK) cells in the treatment of malignant glioma: clinical and experimental studies.
Jacobs SK; Wilson DJ; Melin G; Parham CW; Holcomb B; Kornblith PL; Grimm EA
Neurol Res; 1986 Jun; 8(2):81-7. PubMed ID: 2875409
[TBL] [Abstract][Full Text] [Related]
16. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors.
Sankhla SK; Nadkarni JS; Bhagwati SN
J Neurooncol; 1996 Feb; 27(2):133-40. PubMed ID: 8699235
[TBL] [Abstract][Full Text] [Related]
17. [Induction of LAK cells and CTL in patients with brain tumor and research of its clinical application].
Moriki A
Nihon Geka Hokan; 1989 Jan; 58(1):107-18. PubMed ID: 2802908
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma. Preliminary report.
Jacobs SK; Wilson DJ; Kornblith PL; Grimm EA
J Neurosurg; 1986 May; 64(5):743-9. PubMed ID: 3517250
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of cytolytic activity and cell surface phenotypes of lymphokine activated killer cells stimulated with R-IL 2 and an anti-CD 3 antibody].
Kikuchi T; Sakai H; Nakamura N; Watanabe M; Ohno T
No To Shinkei; 1990 Jun; 42(6):575-80. PubMed ID: 2119634
[TBL] [Abstract][Full Text] [Related]
20. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor.
Merchant RE; Merchant LH; Cook SH; McVicar DW; Young HF
Neurosurgery; 1988 Dec; 23(6):725-32. PubMed ID: 2851116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
